From Diwali 2025 to Diwali 2026: How Sensex, Nifty 50, rupee, crude oil changed in Samvat 2082 | What lies ahead?
Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓The Nifty 50 fell 2.59% and the Sensex fell 3.35% between Diwali 2025 and Diwali 2026.
- ✓While Indian equities lagged, commodities like crude oil surged 54.11%.
- ✓Analysts said Indian equities have a bullish near-term outlook, though many investors got cautious as the rupee weakened and sectoral performance on Dalal Street remained divided.
Story at a Glance
- Category
- Indian Markets
- Reported By
- mint
- Reading Speed
- 8 Minute(s)
- Market Focus
- India Economy
After a sharp seven-session rally, technical analysts said Indian equities have a bullish near-term outlook, with key resistance and support levels guiding the next move. They cautioned that elevated momentum and recent gains could prompt profit-taking.
Samvat 2082 was a year of divergence across global and domestic financial markets, with Indian equities lagging several major international benchmarks even as commodities rallied sharply and the rupee weakened against the US dollar. The Nifty 50 declined 2.59% and the Sensex fell 3.35% between Diwali 2025 and Diwali 2026, while the Nifty Midcap 150 and Nifty Smallcap 250 managed modest gains of 0.90% and 0.29%, respectively. In contrast, Japan's Nikkei surged 13.08%, South Korea's KOSPI jumped 23.63% and the FTSE advanced 11.26%, reflecting stronger gains across major global markets.
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
mint
Read the full, original unfiltered story directly on the publisher's portal.
This brief is for information only and is not investment advice. ArthNow is not a SEBI-registered investment adviser and does not publish buy or sell recommendations. Original reporting is credited to the publisher named above. Read our editorial policy or report an error.